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ECDC and EMCDDA Guidance: Prevention and Control
of Infectious Diseases among People Who Inject Drugs [1]
draws on scientific evidence to identify key components
of infectious disease interventions for people who inject
drugs (PWID). This commentary presents an assessment
of the document from the perspective of five Spanish
drug user organisations. In addition to noting ways in
which we think the guidance might be strengthened, we
also will discuss structural factors that hinder the imple-
mentation of disease prevention measures in PWID
populations.
While the following discussion of ECDC and
EMCDDA Guidance makes it clear that more attention
needs to be given to some important issues, we would
like to emphasise that our intention is not to question
the overall value of this document. In fact, we would be
very pleased to see European countries implement the
seven key intervention components that it recommends:
• clean drug injection equipment;
• vaccination;
• drug dependence treatment;
• testing for HIV, hepatitis B, hepatitis C, tuberculosis
and other infections;
• infectious disease treatment;
• health promotion; and
• targeted delivery of services
The first issue we would like to highlight is the appar-
ent lack of effort by the European Centre for Disease Pre-
vention and Control (ECDC) and European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) to
involve affected communities in the development of the
guidance document. While we cannot positively deter-
mine the backgrounds of all of the authors and technical
advisory group members, our guess is that out of the
almost 50 people named, only one is a member of our
community. Not only is this not right, but surely an
opportunity was missed to include input which would
have improved the value of the recommendations. In
general, we think that in any elaboration of drug policy,
PWID should be involved from the beginning. However,
we are aware that in order to achieve this aim, it is
important to potentiate the empowerment of our com-
munity, which is often found living in situations of social
exclusion and marginalisation, partly because of stigma
and discrimination. This makes it difficult for us to
acquire the basic means to participate and to have our
voices heard.
A notable shortcoming that we have identified regarding
the ECDC and EMCDDA Guidance is a lack of attention
to how gender and cultural issues should be taken into
account in efforts to reach and assist the full array of
PWID who need services. For example, women usually are
a minority of clients in drug user services. It is easy to
overlook gender-specific issues that they face, such as
power dynamics that lead to higher-risk sexual practices
and to unsafe injecting practices imposed by male inject-
ing partners. Migrants and cultural minorities tend to
have less contact with mainstream health services and
drug services, and behaviour-change interventions for
these groups need to be culturally sensitive in order to be
effective.
Another matter that requires greater attention, in our
opinion, is the role of safe consumption rooms. The
ECDC and EMCDDA Guidance briefly discusses safe
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consumption rooms (which it refers to as “supervised
injecting facilities”) as one of multiple aspects of safer
injecting behaviour. For many of us who do not have a
place to inject or who fear the risk of overdose, safe
consumption rooms provide a much-needed alternative
to the streets. Therefore we recommend that safe con-
sumption rooms be designated a key intervention along
with the other key interventions named in the guidance.
In any strategic planning, communities of people who
use drugs should be considered as potential care providers
for our peers. We greatly appreciate the consideration
given to this issue in the guidance, and we would like to
comment further on two specific factors. First, the ability
of some active drug users to implement prevention activ-
ities presents an important opportunity because these indi-
viduals hold a unique position. They have ongoing contact
with the target population, and they can more easily reach
some hidden subgroups of drug users. This interaction
happens in key moments when prevention can be more
effective. Secondly, there is a need to support and care for
former drug users engaged in the implementation of peer
interventions because of the potential impact that this
work can have on their own recovery process. Former
drug users need therapeutic supervision in this situation,
preferably from people who are not co-workers.
Structural interventions are understandably beyond the
scope of the ECDC and EMCDDA Guidance, which
seeks to identify good practices directly related to service
provision. Nonetheless we believe that it is imperative for
all stakeholders involved in implementing the guidance to
take into account structural barriers and to be supportive
of efforts to remove these barriers.
First, there is a need to review the international con-
ventions that criminalise the use of drugs and push
PWID into illegal situations where it is more difficult
for us to make use of effective prevention measures.
Secondly, the ongoing stigmatization of illegal drug use
limits service provision as well as hindering our access
to existing services. Drug use-associated stigma also
conditions the attitudes of health professionals, law
enforcement personnel, and others who interact closely
with PWID, making it more difficult for us to adopt the
preventive measures recommended in the ECDC and
EMCDDA Guidance. Important steps to help overcome
stigma and discrimination include changing the
approach to drug use from a legal to a health problem,
making society understand addiction as a disease with
its own complexities, and giving voice to PWID.
We would like to close by inviting readers to reflect on
three questions about the ECDC and EMCDDA Guidance,
noting that the document was published in 2011 and that
some of the key interventions are supported by a solid
evidence base that has been in existence for many years.
First, why is there so often a lack of political will to
implement these interventions? Secondly, why is their
implementation in prisons so low? And finally, why is
their level of implementation so different across European
countries?
It would be difficult to find another at risk-population
whose needs have been so widely ignored. Our commu-
nity’s capacity for lobbying and advocating is still so
weak that we daily encounter the denial of basic rights
such as the opportunity to access these interventions.
Give us voice and respect, more often and in more
situations, and we are sure that this will make a differ-
ence in the prevention of drug-related harm, including
harm from the transmission of hepatitis C and other
bloodborne viruses. In accordance with the preceding
observations, we suggest that ECDC and EMCDDA
should also explore ways to consult with people who
inject drugs on an ongoing basis regarding the issues
that affect us.
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